Download Free Drug Discovery And Development Prospects And Challenges Book in PDF and EPUB Free Download. You can read online Drug Discovery And Development Prospects And Challenges and write the review.

This book is written to provide a brief overview concerning the latest drug discovery and its development based on the research studies that have been carried out until the present. The idea of preparing this book was inspired by the Holy Qur’an and the hadith, which guides us in all aspects of life, including disease management and treatment. This was supported by the traditional use of natural medicine by our ancestors. From the scientific point of view, we translate all those knowledge and information to be evidence-based modern medicines. We practised the common process of drug discovery development by identifying the potential molecule, followed by in vitro and in vivo experiments. The formulation is a crucial process to produce an efficient and effective drug delivery. Not to forget the future vision that “things would not give any meaning if it is not giving benefit to the people”. Commercialisation is one of the approaches to promote the product across the market and community. The book ends with the current issue of the COVID-19 global pandemic with regards to the treatment, natural medicine, and vaccination.
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
The fact that, of the approximately 600,000 plant species existing on the earth, only some 5 % have been specifically investigated chemically or pharmacologi cally, is a challenge to chemists spezializing in na tural substances and to pharmacologists. In view of the limited number of research capacities and the ever diminishing financial means, this challenge can only be met if, together with an improvement and refinement of methods of analysis, medicinal plant research is carried out on a broader interdisciplinary basis, with comparable, scientifically recognized screening methods, and if it is better coordinated, with greater use of modern documentation means. It is thus necessary in the future to concentrate specifically on projects leading to the development of new medicinal prepara tions. The plenary lectures hold in the present symposium of the 1st International Congress for Research on Medi cinal Plants reflect these efforts and tendencies. At the same time they provide a survey of some of the fields of medicinal plant research which are at present most actual and most intensively researched. They range from plant screening, isolation and structure eluci dation of new principles, to the therapeutical opti mization of a natural product. The lectures given at this congress show clearly the necessity, in addition to national phytochemical so cieties, for a central international organisation, in which all active medicinal plant researchers in the world are included. Their aim should be to provide the impulse for more optimal, rational research, aimed at the solution of specific projects.
Following significant advances in deep learning and related areas interest in artificial intelligence (AI) has rapidly grown. In particular, the application of AI in drug discovery provides an opportunity to tackle challenges that previously have been difficult to solve, such as predicting properties, designing molecules and optimising synthetic routes. Artificial Intelligence in Drug Discovery aims to introduce the reader to AI and machine learning tools and techniques, and to outline specific challenges including designing new molecular structures, synthesis planning and simulation. Providing a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia.
Social Aspects of Drug Discovery, Development and Commercialization provides an insightful analysis of the drug discovery and development landscape as it relates to society. This book examines the scientific, legal, philosophical, economic, political, ethical and cultural factors that contribute to drug development. The pharmaceutical industry is under scrutiny to develop safer and more effective drugs in a quicker and more affordable manner. Recent criticism and debates have emphasized varying opinions on the issues concerning the drug discovery and development process. This book provides thoughtful and valuable discussions and analysis of the social challenges and potential opportunities through all stages of the pharmaceutical process, from inception through marketing. With a unique focus on the social factors that increasingly play a role in how drug development is planned, structured, and executed throughout the drug product lifecycle, this is an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society. - Organized in a sequence of interrelated theories and principles that provide the foundation for increased understanding of the relevant social aspects - Includes analysis of important new advances, key scientific and strategic issues, and overviews of recent progress in drug development - Provides a global perspective with examples from developed areas, such as the US, Japan, Canada and Europe, as well as faster-growing and emerging economies including Brazil, Russia, India, and China - Serves as an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.
Decades of research have demonstrated that children do not respond to medications in the same way as adults. Differences between children and adults in the overall response to medications are due to profound anatomical, physiological, and developmental differences. Although few would argue that children should receive medications that have not been adequately tested for safety and efficacy, the majority of drugs prescribed for children-50 to 75 percent-have not been tested in pediatric populations. Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence. Addressing the Barriers to Pediatric Drug Development is the summary of a workshop, held in Washington, D.C. on June 13, 2006, that was organized to identify barriers to the development and testing of drugs for pediatric populations, as well as ways in which the system can be improved to facilitate better treatments for children.
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.
Nature has consistently provided human beings with bioactive compounds that can be used directly as drugs or indirectly as drug leads. Some of the major classes of natural bioactive compounds include phenolics, alkaloids, tannins, saponins, lignin, glycosides, terpenoids, and many more. They possess a broad range of biological activities and are primarily useful in the treatment of various health issues. At the same time, the search for new and novel drugs is never-ending and, despite major advances in synthetic chemistry, nature remains an essential resource for drug discovery. Therefore, more and more researchers are interested in understanding the chemistry, clinical pharmacology, and beneficial effects of bioactive compounds in connection with solving human health problems. This book presents a wealth of information on natural metabolites that have been or are currently being used as drugs or leads for the discovery of new drugs. In addition, it highlights the importance of natural products against various human diseases, and their applications in the drug, nutraceuticals, cosmetics and herbal industries. Accordingly, the book offers a valuable resource for all students, educators, and healthcare experts involved in natural product research, phytochemistry, and pharmacological research.